

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

In re: Advanced Bioscience Consumables, Inc.

§
§
§
§

Case No. 23-10368

Debtor(s)

☐ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 06/30/2025

Petition Date: 03/29/2023

Plan Confirmed Date: 07/19/2023

Plan Effective Date: 08/03/2023

This Post-confirmation Report relates to: ☐ Reorganized Debtor

☒ Other Authorized Party or Entity: Liquidation Trustee

Name of Authorized Party or Entity

/s/ Katelin A. Morales

Signature of Responsible Party

07/21/2025

Date

Katelin A. Morales

Printed Name of Responsible Party

Potter Anderson & Corroon LLP
1313 N. Market St., 6th Floor
Wilmington, DE 19801-6108
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$63,644	\$661,744
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$63,644	\$661,744

Part 2: Preconfirmation Professional Fees and Expenses

a.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>		\$0	\$0	\$0	\$0
	<i>Itemized Breakdown by Firm</i>					
		Firm Name	Role			
	i			\$0	\$0	\$0
	ii					
	iii					
	iv					
	v					
	vi					
	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					
	xv					
	xvi					
	xvii					
	xviii					
	xix					
	xx					
	xxi					
	xxii					
	xxiii					
	xxiv					
	xxv					
	xxvi					
	xxvii					
	xxviii					
	xxix					

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xl ii						
xl iii						
xl iv						
xl v						
xl vi						
xl vii						
xl viii						
xl ix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						
xc						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						
xcix						
c						
ci						

b.			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor		\$0	\$0	\$0	\$0
	<i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
i			\$0	\$0	\$0	\$0
ii						
iii						
iv						
v						
vi						

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					
	xv					
	xvi					
	xvii					
	xviii					
	xix					
	xx					
	xxi					
	xxii					
	xxiii					
	xxiv					
	xxv					
	xxvi					
	xxvii					
	xxviii					
	xxix					
	xxx					
	xxxi					
	xxxii					
	xxxiii					
	xxxiv					
	xxxv					
	xxxvi					
	xxxvii					
	xxxviii					
	xxxix					
	xl					
	xli					
	xlii					
	xliii					
	xliv					
	xlv					
	xlvi					
	xlvii					
	xlviii					

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvi						
lxxxvi						
lxxxix						
xc						

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)			\$0	\$0	\$0	\$0

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$0	\$0	0%
d. General unsecured claims	\$1,250,000	\$0	\$0	\$36,000,000	0%
e. Equity interests	\$0	\$0	\$0		

Part 4: Questionnairea. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: 12/31/2025b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Advanced Bioscience Consumables, Inc.

Case No. 23-10368

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Peter Kravitz

Signature of Responsible Party

Liquidation Trustee, in his sole capacity

Title

Peter Kravitz


Printed Name of Responsible Party

07/2/2025


Date

Debtor's Name Advanced Bioscience Consumables, Inc.


Case No. 23-10368




Page 1



Other Page 1




Page 2 Minus Tables




Bankruptcy Table 1-50

Debtor's Name Advanced Bioscience Consumables, Inc.


Case No. 23-10368




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

In re Advanced Bioscience Consumables, Inc.,
Case No. 23-10368

Notes to Post-Confirmation Report for Quarter Ended June 30, 2025

Regarding Part 2: Preconfirmation Professional Fees and Expenses:

Pursuant to the *Joint Chapter 11 Plan of Reorganization of SiO2 Medical Products, Inc., and Its Debtor Affiliates* (the “Plan”) and the Liquidation Trust Agreement executed by the Liquidation Trustee and the Debtors (the “Liquidation Trust Agreement”), Peter Kravitz is the duly appointed trustee of the Liquidation Trust. Pursuant to the Plan, the Reorganized Debtors are charged with, among other things, paying Professional Fee Claims to Professionals. *See* Plan, Art. II(B)(1). Accordingly, the Liquidation Trustee has no insight or information regarding the payment of professional fees and expenses.

Regarding Part 3(a) – (c) and (e):

The Liquidation Trustee is charged with, among other things, effectuating the distributions to Holders of Allowed General Unsecured Claims and Holders of Allowed Athos Subordinated Claims. Accordingly, Liquidation Trustee has no insight or information regarding the recoveries of the holders of administrative claims, secured claims, priority claims, or equity interests.

Regarding Part 3(d):

“Total Anticipated Payments Under Plan” reflects cash on hand as of the date of the Effective Date provided to the Trust as per the terms of the Plan. This amount is subject to growth based on litigation proceeds and subject to reduction based on, among other things, operating expenses of the Liquidation Trustee and/or the estates.

The claims reconciliation process is ongoing and reporting with respect to “Allowed Claims” is premature at this time. Accordingly, all of the amounts listed under “Allowed Claims,” irrespective of priority level, reflect the estimates set forth in the *Disclosure Statement for the Joint Chapter 11 Plan of Reorganization of SiO2 Medical Products, Inc., and Its Debtor Affiliates* [Docket No. 373]. The Liquidation Trustee reserves all of its rights with respect to the validity, amount, and priority of all claims filed in the chapter 11 cases. Nothing in this post-confirmation report shall constitute an admission that any claim is, in fact, “Allowed.” In addition, all amounts are subject to change as the reconciliation process evolves. Therefore, the “% Paid of Allowed Claims” may be inaccurate as a result.

CERTIFICATE OF SERVICE

I, Katelin A. Morales, do hereby certify that on July 21, 2025, a copy of the foregoing *Chapter 11 Post-Confirmation Report for the Quarter Ending 06/30/2025* was served on the party listed below in the manner indicated.

United States Trustee

Linda Richenderfer

Email: Linda.Richenderfer@usdoj.gov;

ustp.region03@usdoj.gov

Via Email

/s/ Katelin A. Morales

Katelin A. Morales (No. 6683)